Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates

Nat Med. 2021 Jan;27(1):4-5. doi: 10.1038/s41591-020-01172-x.

Molly E Gallagher¹, Andrew J Sieben², Kristin N Nelson³, Alicia N M Kraay³, Walter A Orenstein^{4

5}, Ben Lopman³, Andreas Handel⁶, Katia Koelle^{7

5}

¹ Department of Biology, Emory University, Atlanta, GA, USA. mgallagher@emory.edu.
² School of Medicine, Emory University, Atlanta, GA, USA.
³ Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
⁴ Emory Vaccine Center, School of Medicine, Emory University, Atlanta, GA, USA.
⁵ Emory-UGA Center of Excellence of Influenza Research and Surveillance, Atlanta, GA, USA.
⁶ Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia, Athens, GA, USA.
⁷ Department of Biology, Emory University, Atlanta, GA, USA.

No abstract available

Publication types